
IASLC World Conference on Lung Cancer (WCLC) - KoreaWCLC
IASLC World Conference on Lung Cancer (WCLC) - Korea Profile
The World Conference on Lung Cancer (WCLC) in Korea is the largest academic conference in the global lung cancer field. Focusing on basic research, clinical treatment advancements, and the exploration of innovative therapies, it serves as a core platform driving the development of the lung cancer sector. Notably, an increasing number of research studies from China have been presented on this stage in recent years.
Organized by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer (WCLC) stands as one of the most influential global academic events in the lung cancer field. WCLC is not only a premier academic hub for physicians to learn about cutting-edge advancements and clinical trends, but also an exceptional stage for researchers to share their findings and broaden their international perspectives.
The Korea WCLC will feature 18 session types and over 50 oral abstract presentations, focusing on the latest advancements across various domains including lung cancer risk control, biology, screening, local therapy, immunotherapy, and targeted therapy, centrally showcasing the year's key breakthroughs in lung cancer research.
Experts and scholars from around the world will gather to discuss cutting-edge topics such as precision medicine, immunotherapy, targeted therapy, early screening, and patient management through keynote speeches, specialized seminars, and poster sessions.
Exhibitor List
IASLC World Conference on Lung Cancer (WCLC) - Korea Product Range
Core Therapeutic Areas
Non-Small Cell Lung Cancer (NSCLC): Covers first-line treatment for squamous/non-squamous NSCLC, exploring the application of combination immunotherapy in patients with brain metastases and in the perioperative setting.
Small Cell Lung Cancer (SCLC): Presents treatment advancements for extensive-stage SCLC, including combination regimens of immunotherapy and targeted therapy.
Breakthroughs in Innovative Therapies
Immunotherapy: Updated clinical data on PD-1/PD-L1 inhibitors (, Hansizhuang®, HLX43) and bispecific antibody therapies (, Ivonescimab).
Targeted Therapy: Latest research progress on EGFR mutations (, Aiduotinib) and ALK alterations (, Cadonilimab).
Research on Special Populations
Patients with Brain Metastases: Comparative efficacy of targeted drugs in NSCLC with brain metastases (, Aiduotinib vs. Osimertinib).
Perioperative Management: Potential applications of immunotherapy before and after lung cancer surgery.
Academic Exchange Sessions
The conference features multiple modules, including:
Early Lung Cancer Screening: New technologies such as Low-Dose CT (LDCT) screening.
Advanced-Stage Treatment: Clinical progress of Antibody-Drug Conjugate (ADC) drugs and bispecific antibody therapies.
Special Populations: Treatment protocols for specific subgroups such as pediatric and elderly patients.
IASLC World Conference on Lung Cancer (WCLC) - Korea Booth Sales

IASLC World Conference on Lung Cancer (WCLC) - Korea Ticket Sales

IASLC World Conference on Lung Cancer (WCLC) - Korea Venue
IASLC World Conference on Lung Cancer (WCLC) - KoreaCommunity
IASLC World Conference on Lung Cancer (WCLC) - Korea Booth price

Standard booth Configuration

Blank booth Configuration
IASLC World Conference on Lung Cancer (WCLC) - Korea Process
1.Submit the business license of the company
2.Submit product picture and name
3.Receive exhibition presentation documents and booth drawings
4.Submit booth application form/Sign booth contract
5.Pay the contract booth deposit
6.Prepare for exhibition



















